{
    "body": "Is nintedanib effective for Idiopathic Pulmonary Fibrosis?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25628503", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26261848", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24834811", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26039104", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25430078", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24782550", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26380465", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24556663", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23818761", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24836310", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25767391", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25439569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26346347", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25635490"
    ], 
    "ideal_answer": [
        "Yes, nintedanib is approved for Idiopathic Pulmonary Fibrosis treatment.  Nintedanib was shown to slow the decline in lung function, decrease acute exacerbations, decrease the annual rate of decline in forced vital capacity and increase time to acute exacerbation."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054990", 
        "http://www.disease-ontology.org/api/metadata/DOID:0050156"
    ], 
    "type": "yesno", 
    "id": "56c048e2ef6e39474100001d", 
    "snippets": [
        {
            "offsetInBeginSection": 532, 
            "offsetInEndSection": 689, 
            "text": "In this review, we present the positive results of recently published clinical trials regarding therapy for IPF, with emphasis on pirfenidone and nintedanib.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380465", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 83, 
            "text": "Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346347", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 629, 
            "offsetInEndSection": 1217, 
            "text": " In the Phase II TOMORROW trial, treatment with 150 mg of nintedanib twice daily showed a trend to slow the decline in lung function and significantly decrease acute exacerbations in patients with IPF, while showing an acceptable safety profile. The Phase III INPULSIS trials demonstrated a significant decrease in the annual rate of decline in forced vital capacity in IPF patients treated with 150 mg nintedanib twice daily. In the INPULSIS-2 trial, the time to the first acute exacerbation significantly increased in IPF patients who were treated with 150 mg of nintedanib twice daily.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346347", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1249, 
            "offsetInEndSection": 1372, 
            "text": " Effects on collagen secretion were compared with those of the drugs nintedanib and pirfenidone, recently approved for IPF.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26039104", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 124, 
            "offsetInEndSection": 558, 
            "text": "Nintedanib, an orally available, small-molecule tyrosine kinase inhibitor with selectivity for vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) receptors has recently been shown, in two pivotal phase III studies, to effectively slow IPF disease progression. Consequently, nintedanib was given accelerated approval by the FDA in October 2014 for the treatment of IPF. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261848", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1027, 
            "offsetInEndSection": 1217, 
            "text": "Most recently, pirfenidone and nintedanib, two compounds with pleiotropic anti-fibrotic properties, have been proven effective in reducing functional decline and disease progression in IPF. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25767391", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 289, 
            "text": "Meningococcal group B vaccine (Trumenba) to prevent more types of invasive meningococcal disease; antihemophilic factor (recombinant), porcine sequence (Obizur) to treat bleeding from acquired hemophilia A; and pirfenidone (Esbriet) and nintedanib (Ofev) for idiopathic pulmonary fibrosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25628503", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 412, 
            "offsetInEndSection": 628, 
            "text": " More importantly, the period ends with the publication of two groundbreaking studies that confirmed that two drugs, pirfenidone and nintedanib, slowed disease progression, leading to a historic approval by the FDA. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25635490", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 630, 
            "text": "Nintedanib (Ofev(\u00ae)) is an orally available, small, multiple receptor tyrosine kinase inhibitor developed by Boehringer Ingelheim for the treatment of idiopathic pulmonary fibrosis (IPF) and cancer. Nintedanib received its first global approval in the US in October 2014 for the treatment of IPF. Nintedanib has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the treatment of IPF, and for the second-line treatment in combination with docetaxel of locally advanced, metastatic or locally recurrent non-small cell lung cancer of adenocarcinoma tumour histology. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430078", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 926, 
            "offsetInEndSection": 1037, 
            "text": "This article summarizes the milestones in the development of nintedanib leading to this first approval for IPF.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430078", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 67, 
            "text": "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 75, 
            "text": "Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782550", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 93, 
            "text": "Nintedanib is in clinical development as a treatment for idiopathic pulmonary fibrosis (IPF).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24834811", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 103, 
            "text": "Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818761", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 2247, 
            "offsetInEndSection": 2383, 
            "text": "These results suggest that nintedanib may impact the progressive course of fibrotic lung diseases such as idiopathic pulmonary fibrosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24556663", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 322, 
            "text": "Findings from recently published placebo-controlled trials in idiopathic pulmonary fibrosis have established that pirfenidone and nintedanib prevent about 50% of the decline in forced vital capacity typically seen in this disease; future trials are therefore unlikely to use placebo as a control group for ethical reasons.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25439569", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 131, 
            "text": "The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the treatment of idiopathic pulmonary fibrosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24556663", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 290, 
            "offsetInEndSection": 470, 
            "text": "A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 123, 
            "offsetInEndSection": 304, 
            "text": "A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 106, 
            "offsetInEndSection": 436, 
            "text": "Data from the Phase II TOMORROW study suggested that nintedanib 150\ufffdmg twice daily had clinical benefits with an acceptable safety profile.METHODS: The INPULSIS\ufffd trials are replicate Phase III, randomized, double-blind, studies comparing the efficacy and safety of nintedanib 150\ufffdmg twice daily with placebo in patients with IPF. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24834811", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 199, 
            "offsetInEndSection": 297, 
            "text": "Nintedanib received its first global approval in the US in October 2014 for the treatment of IPF. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430078", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1615, 
            "offsetInEndSection": 2143, 
            "text": "The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 123, 
            "offsetInEndSection": 563, 
            "text": "A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 297, 
            "text": "Nintedanib (Ofev(\ufffd)) is an orally available, small, multiple receptor tyrosine kinase inhibitor developed by Boehringer Ingelheim for the treatment of idiopathic pulmonary fibrosis (IPF) and cancer. Nintedanib received its first global approval in the US in October 2014 for the treatment of IPF. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430078", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 84, 
            "text": "Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26346347", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 112, 
            "offsetInEndSection": 542, 
            "text": "A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24836310", 
            "endSection": "abstract"
        }
    ]
}